Osteoporosis Medical Services in China

Osteoporosis is a systemic skeletal disorder characterized by reduced bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to low-trauma fractures—most commonly at the spine, hip, and distal radius. It is a hallmark condition in endocrinology due to its strong association with hormonal imbalances, particularly estrogen deficiency in postmenopausal women and testosterone decline in aging men, as well as disorders of calcium, vitamin D, parathyroid hormone (PTH), and cortisol metabolism. Pathogenically, osteoporosis arises from an imbalance between bone resorption (mediated by overactive osteoclasts) and bone formation (impaired osteoblast function). Chronic inflammation, oxidative stress, mitochondrial dysfunction in bone cells, and dysregulated RANK/RANKL/OPG signaling further accelerate bone loss. Secondary causes—including glucocorticoid therapy, hyperthyroidism, primary hyperparathyroidism, type 1 diabetes, chronic kidney disease, and malabsorptive gastrointestinal disorders—account for up to 30% of cases and must be systematically evaluated in endocrine workup. Epidemiologically, osteoporosis affects over 90 million people in China alone, with prevalence rising sharply after age 50: approximately 32% of women and 6% of men aged ≥65 meet diagnostic criteria (based on WHO BMD T-score ≤−2.5). Globally, one in three women and one in five men over 50 will experience an osteoporotic fracture in their lifetime. Key modifiable risk factors include prolonged glucocorticoid use (>3 months, ≥5 mg prednisone/day), smoking, excessive alcohol intake (>3 drinks/day), sedentary lifestyle, low calcium/vitamin D intake, and chronic protein-energy malnutrition. Non-modifiable risks include advanced age, female sex, early menopause (<45 years), family history of hip fracture, and certain genetic variants (e.g., LRP5, SOST). Importantly, osteoporosis is often asymptomatic until a fragility fracture occurs—making it a 'silent epidemic.' Vertebral compression fractures may cause height loss, kyphosis, or chronic back pain; hip fractures carry high morbidity (20–25% 1-year mortality) and functional decline. Beyond physical disability, patients frequently report anxiety about falling, social withdrawal, depression, sleep disturbances, and diminished independence—significantly impairing health-related quality of life (HRQoL), as measured by tools like EQ-5D and SF-36. Early diagnosis via dual-energy X-ray absorptiometry (DXA), combined with FRAX® fracture risk assessment, enables timely intervention. Endocrinologists play a central role in identifying secondary causes, optimizing hormonal and metabolic parameters, and personalizing pharmacotherapy—including bisphosphonates, denosumab, teriparatide, romosozumab, and selective estrogen receptor modulators—alongside nutritional counseling, fall prevention, and supervised exercise.

Osteoporosis is a systemic skeletal disorder characterized by reduced bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to low-trauma fractures—most commonly at the spine, hip, and distal radius. As an endocrine disorder frequently managed within Endocrinology departments, osteoporosis requires comprehensive, individualized, and long-term management strategies grounded in evidence-based medicine.

Conservative treatment forms the cornerstone of osteoporosis management and must be initiated alongside pharmacologic therapy or as primary intervention for individuals with low fracture risk (e.g., T-score ≥ −2.5 without prior fragility fracture). Lifestyle modification includes adequate calcium intake (1000–1200 mg/day from diet and/or supplementation, adjusted for gastric acid status and renal function), vitamin D optimization (800–2000 IU/day to maintain serum 25(OH)D ≥ 30 ng/mL), and progressive resistance and balance training. Weight-bearing aerobic exercise (e.g., brisk walking, stair climbing) for ≥150 minutes/week combined with supervised strength training twice weekly significantly improves bone mineral density (BMD), reduces fall risk, and enhances neuromuscular coordination. Fall prevention is critical: home safety assessments, vision screening, medication review (especially sedatives and antihypertensives associated with orthostasis), and podiatric evaluation for gait abnormalities are essential components. Smoking cessation and alcohol moderation (<14 units/week for women, <21 for men) are strongly advised, given their direct negative effects on osteoblast activity and bone turnover.

Pharmacotherapy is indicated for patients with a prior fragility fracture, T-score ≤ −2.5 at the lumbar spine, femoral neck, total hip, or one-third radius, or those with high 10-year fracture probability per FRAX® (≥3% for hip or ≥20% for major osteoporotic fracture). First-line agents include oral bisphosphonates (alendronate, risedronate, ibandronate), which inhibit osteoclast-mediated bone resorption. Intravenous zoledronic acid (5 mg annually) offers superior adherence and efficacy in frail or gastrointestinal-intolerant patients. Denosumab—a human monoclonal antibody targeting RANKL—is administered subcutaneously every 6 months and demonstrates robust anti-fracture efficacy, particularly in high-risk populations; however, it requires strict adherence due to rapid bone loss upon discontinuation. Anabolic agents are reserved for severe cases (e.g., multiple vertebral fractures, T-score ≤ −3.0, or treatment failure): teriparatide (PTH 1–34) and abaloparatide stimulate osteoblast activity and new bone formation over 18–24 months, followed by an antiresorptive agent to preserve gains. Romosozumab—a sclerostin inhibitor—offers dual action (anabolic followed by antiresorptive effect) and is approved for postmenopausal women at very high fracture risk, though cardiovascular risk assessment is mandatory prior to initiation. All pharmacotherapies require baseline renal function testing, dental evaluation (to mitigate osteonecrosis of the jaw), and monitoring of bone turnover markers (e.g., serum CTX, P1NP) and BMD via DXA every 1–2 years.

Surgical treatment is not curative but addresses acute complications. Vertebral compression fractures refractory to conservative care may benefit from minimally invasive procedures: kyphoplasty (balloon inflation followed by cement augmentation) and vertebroplasty (direct cement injection) restore vertebral height, alleviate pain, and improve mobility—though patient selection is crucial (acute/subacute fractures <6 months old, no posterior wall compromise, no active infection). Hip fractures necessitate urgent orthopedic surgical fixation (e.g., intramedullary nailing for intertrochanteric fractures) or arthroplasty (hemiarthroplasty or total hip replacement for femoral neck fractures), followed by immediate endocrine evaluation and initiation of osteoporosis therapy to prevent subsequent fractures. Spinal fusion is rarely indicated and only considered for progressive deformity or neurological compromise unresponsive to nonoperative measures.

China offers distinct advantages in osteoporosis care, including nationally standardized clinical pathways endorsed by the Chinese Society of Endocrinology and integrated into the National Health Commission’s Chronic Disease Management Program. High-volume tertiary hospitals deploy AI-assisted DXA interpretation and automated FRAX® integration into electronic health records, enabling real-time fracture risk stratification. Traditional Chinese Medicine (TCM) adjuncts—such as Bushen Zhuanggu decoction—are increasingly studied in randomized trials and used alongside conventional therapy for symptom control and bone metabolism modulation, though evidence remains complementary rather than substitutive. China’s centralized drug procurement system has dramatically reduced costs of generic bisphosphonates and denosumab, improving accessibility. Moreover, community-based 'Bone Health Stations' provide free BMD screening, nutrition counseling, and supervised exercise programs—enhancing early detection and longitudinal adherence. Multidisciplinary Fracture Liaison Services (FLS), now implemented in >200 hospitals nationwide, ensure systematic identification of fragility fracture patients and timely referral to endocrinology, reducing secondary fracture rates by up to 50%.

Recovery and long-term maintenance emphasize continuity of care. Patients should undergo structured follow-up: clinical assessment every 3–6 months initially, then annually; repeat DXA at 1–2 years to evaluate treatment response (a BMD increase ≥3% at spine or ≥2% at hip is considered favorable); and serial bone turnover markers to assess biological adherence. Nutrition counseling should reinforce protein adequacy (1.0–1.2 g/kg/day) to support muscle-bone crosstalk. Fall prevention must persist lifelong—annual home safety re-evaluation and quarterly balance assessments are recommended for adults >70 years. Psychosocial support is integral: depression and fear of falling correlate strongly with functional decline and poor treatment adherence. Finally, shared decision-making—including discussion of treatment duration, risks (e.g., atypical femoral fracture with prolonged bisphosphonate use), and goals of care—is essential to sustain engagement. With coordinated endocrine-led management, most patients achieve stable BMD, reduced fracture incidence, and preserved independence—underscoring that osteoporosis, while chronic, is highly treatable when addressed proactively and comprehensively.